Search Articles

View query in Help articles search
e.g. mhealth

Search Results (1 to 3 of 3 Results)

Download search results: CSV END BibTex RIS

The Association Between Physical Distancing Behaviors to Avoid COVID-19 and Health-Related Quality of Life in Immunocompromised and Nonimmunocompromised Individuals: Patient-Informed Protocol for the Observational, Cross-Sectional EAGLE Study

The Association Between Physical Distancing Behaviors to Avoid COVID-19 and Health-Related Quality of Life in Immunocompromised and Nonimmunocompromised Individuals: Patient-Informed Protocol for the Observational, Cross-Sectional EAGLE Study

However, the population of immunocompromised individuals is heterogeneous—the degree of immunosuppression depends on the underlying disease or the duration of the condition and the type of immunosuppressive treatment [3,17-19]. Moreover, there is a lack of consensus on how severity should be categorized among immunocompromised individuals (eg, who should be considered moderately vs severely immunocompromised) [9-11,15].

Paul Williams, Timothy A Herring, Renata T C Yokota, Tiago Maia, Sudhir Venkatesan, James C Marcus, Gabriella Settergren, Sofie Arnetorp, Andrew Lloyd, Johan L Severens, James W Varni, Sharon Dixon, Lweendo Hamusankwa, Philip A Powell, Sylvia Taylor, John E Ware Jr, Marieke Krol

JMIR Res Protoc 2024;13:e52643

Download Citation: END BibTex RIS

Download PDF Download XML
Article has an altmetric score of 1

Defining and Risk-Stratifying Immunosuppression (the DESTINIES Study): Protocol for an Electronic Delphi Study

Defining and Risk-Stratifying Immunosuppression (the DESTINIES Study): Protocol for an Electronic Delphi Study

This disagreement on what constitutes immunosuppression extends to how best to subdivide this heterogeneous population: out of the binary [4], continuum [5], and hierarchical [6] approaches available, there is currently no gold standard [7]. This inconsistency undermines ambitions for targeted care and disease surveillance as aggregate-level analysis dominates, and subtrends lose visibility [7].

Meredith Leston, José Ordóñez-Mena, Mark Joy, Simon de Lusignan, Richard Hobbs, Iain McInnes, Lennard Lee

JMIR Res Protoc 2024;13:e56271

Download Citation: END BibTex RIS

Download PDF Download XML
Article has an altmetric score of 2

Subclinical and Clinical Outcomes in Patients Coinfected With HIV and Chronic Hepatitis B Virus From Clinical Outpatient Centers in France: Protocol for an Ambispective, Longitudinal Cohort Study

Subclinical and Clinical Outcomes in Patients Coinfected With HIV and Chronic Hepatitis B Virus From Clinical Outpatient Centers in France: Protocol for an Ambispective, Longitudinal Cohort Study

Immunosuppression was for the most part mild with median CD4+ cell count at 548/mm3 (IQR 426-719), and HIV RNA was predominately undetectable (136/139, 97.8% with available data). Most patients were HBe Ag negative (111/134, 82.8% with available data) and many had undetectable HBV DNA (124/132, 93.9% with available data) with a median HBV-DNA VL of 2.53 log10 IU/m L (IQR 2.53-2.95) for those with detectable HBV DNA. Most patients (114/147, 77.6%) underwent either TFV or TFV alafenamide–containing ART.

Anders Boyd, Lorenza N C Dezanet, Raisha Kassime, Patrick Miailhes, Caroline Lascoux-Combe, Julie Chas, Pierre-Marie Girard, Joël Gozlan, Fabien Zoulim, Constance Delaugerre, Hayette Rougier, Karine Lacombe

JMIR Res Protoc 2021;10(4):e24731

Download Citation: END BibTex RIS

Download PDF Download XML
Article has an altmetric score of 2